news.cision.com

Deliveries have started, and ChromoGenics improved its earningsThird quarter of 2021 · ChromoGenics began in-house production of its dynamic glass ConverLight® Dynamic at the end of May at a slow rate to reduce the risk of production disruptions. During the quarter, the rate of production was gradually increased with several deliveries to our customers. · After ChromoGenics completed the long-term tests of the in-house dynamic glass ConverLight[® ]Dynamic in mid-June, the top priority has been the post-inspection. Our focus is now on increasing the rate of production step by step in

Scandion Oncology announce cancellation of extraordinary general meeting

Scandion Oncology A/S, today announced that the extraordinary general meeting on Wednesday November 17, 2021, has been cancelled.The contemplated extraordinary general meeting in the Company on November 17, 2021 was initially requested by shareholders representing 5.71% of the registered share capital. The Board of Directors has now been informed that the request for an extraordinary general meeting with the proposed agenda is no longer supported by shareholders representing at least 5% of the registered share capital. For that reason, the planned extraordinary general meeting is cancelled.

Strong sales growth with a significant improvement in operating income

PowerCell Sweden AB grew its sales by 171 percent during the third quarter 2021, from MSEK 17 to MSEK 45. Operating income improved to MSEK -12 (-28) due to increased sales and strengthened gross margin. Growth was driven by increased demand in all segments.In terms of sales, the third quarter 2021 was yet another very strong quarter for PowerCell Sweden AB and a new record for a single quarter, in terms of both sales and growth. This was the fourth quarter in a row with record sales in absolute numbers in comparison with corresponding quarters previous years. “The disruptions in our

Sleep Cycle interim report July-September 2021: Accelerated growth and important strategic partnership

Net sales increased 20,9% to SEK 48.8m during the third quarter, corresponding to a 30.0% currency adjusted growth rate. The increase was driven by subscription growth of 13.0%, fueled by high efficiency in marketing spending and income related to a partnership that was entered into together with Samsung. In the partnership with Samsung, Sleep Cycle will be integrated in Samsung’s smart watches and becomes part of Samsung’s health offering.Third quarter summary (July-September 2021) · Net sales increased by 20.9 (30.4 July-September 2020) % and totaled SEK 48,759 (40,336) thousand.

Alligator Announces Poster Presentation on OPTIMIZE-1 at SITC Virtual Annual Meeting 2021

Fri, Nov 12, 2021 08:18 CET

Poster presentation to highlight the design of Optimize-1, evaluating mitazalimab in combination with chemotherapy in patients with metastatic pancreatic ductal adenocarcinomaLund, Sweden, November 12, 2021 – Alligator Bioscience AB (“Alligator” or the “Company”) today announced that the design and scientific rationale of OPTIMIZE-1, Alligator´s phase 2 study (NCT02829099) in 1[st] line metastatic pancreatic cancer in combination with mFOLFIRINOX, will be presented at the Society for Immunotherapy Cancer’s (SITC) 36[th] Annual Meeting & Pre-Conference Programs virtually on November 10[th] –

Notice to the Extraordinary General Meeting of Eevia Health Abp

Notice is given to the shareholders of Eevia Health Abp (Plc) to the Extraordinary General Meeting to be held on 9th of December, 2021 at 1.00 pm at the main office of Eevia Health Plc in Koulukatu 14, Seinäjoki, Finland. The reception of persons who have registered for the meeting and the distribution of voting tickets will commence at 12.30 pm.A. Matters on the agenda of the General Meeting At the General Meeting, the following matters will be considered: 1. Opening of the meeting 2. Calling the meeting to order 3. Election of persons to scrutinize the minutes and to supervise

Alligator Bioscience and Aptevo Therapeutics Announce a Poster Presentation of ALG.APV-527 at SITC Annual Meeting 2021

Data support Advancement into the ClinicLund, Sweden, and Seattle Washington, November 12, 2021 – Alligator Bioscience AB (“Alligator”) and Aptevo Therapeutics (“Aptevo”) today announces preclinical data on ALG.APV-527, a potentially first-in-class bispecific targeting both 4-1BB and tumor antigen 5T4 will be presented in a poster at the Society for Immunotherapy Cancer’s (SITC) 36[th] Annual Meeting, taking place virtually and in-person on November 12[th] – 14[th], 2021 in Washington D.C. The poster highlights preclinical datasets as an overview of the potential indication landscape,

Fiskars Corporation - Notification of management's transactions - Ahlström (acquisition)

Fiskars CorporationManagers' transactionsNovember 12, 2021 at 09:15 EET Fiskars Corporation - Notification of management's transactions Fiskars Corporation has received the following notification pursuant to Article 19 of the Market Abuse Regulation: Fiskars Oyj Abp - Managers' Transactions____________________________________________ Person subject to the notification requirementName: Ahlström, Anja NathaliePosition: Chief Executive OfficerIssuer: Fiskars Oyj AbpLEI: 743700BKTW4EQIVKYY42 Notification type: INITIAL NOTIFICATIONReference number:

Fiskars Corporation - Notification of management's transactions - Siitonen (acquisition)

Fiskars CorporationManagers' transactionsNovember 12, 2021 at 09:15 EET Fiskars Corporation - Notification of management's transactions Fiskars Corporation has received the following notification pursuant to Article 19 of the Market Abuse Regulation: Fiskars Oyj Abp - Managers' Transactions____________________________________________ Person subject to the notification requirementName: Siitonen, JussiPosition: Chief Financial OfficerIssuer: Fiskars Oyj AbpLEI: 743700BKTW4EQIVKYY42 Notification type: INITIAL NOTIFICATIONReference number: 743700BKTW4EQIVKYY42_

High acquisition pace brought strong growth

Fri, Nov 12, 2021 08:10 CET

Third quarter 2021 · Net revenue increased by 28% to SEK 577 million (450). · Adjusted EBITA increased to SEK 82 million (76), corresponding to an adjusted EBITA margin of 14.2% (16.8). · EBIT amounted to SEK 11 million (73). · Adjusted EBIT amounted to SEK 69 million (73). · Adjusted profit for the period amounted to SEK 4 million (27). · Earnings per share, basic and diluted, totalled SEK -0.45 (0.24). · Cash flow from operating activities amounted to SEK 43 million (38). Costs affecting comparability amounted to SEK 58 million (0) in the third quarter of 2021

Further efficacy data from the COVID-19 clinical Phase I/II study with ABNCoV2 confirms strong positive results

Hørsholm, Denmark, November 12, 2021 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that the remaining virus neutralization data, for the two highest dose ranges of 50 μg and 70 μg, have now been published from the COUGH-1 COVID-19 Phase I/II clinical trial to evaluate the ABNCoV2 vaccine. The headline results met its safety and efficacy endpoints also for these dose ranges, and thus for the study in its entirety.COUGH-1 headline results Positive initial data from the first-in-human study of ABNCoV2, the capsid virus like particle (

Autoliv investing in Japan to optimize footprint for future growth

Fri, Nov 12, 2021 08:04 CET

(Stockholm, Sweden, November 12, 2021) – Autoliv, Inc. (NYSE: ALV and SSE: ALIVsdb), the worldwide leader in automotive safety systems, today announced the launch of a Japan footprint optimization plan, including the establishment of a new state of the art production facility in central Japan and phasing out two existing plants. The investment demonstrates Autoliv’s commitment to its customers and to the Japanese market. Supported by Autoliv’s strong engineering and manufacturing capabilities in Japan, we have gained a leading position with Japanese car manufactures across the world. In

K-Fastigheter strengthens Group Management

Fri, Nov 12, 2021 08:03 CET

K-Fast Holding AB (“K-Fastigheter”) has today appointed Magnus Persson as a new member of Group Management.Magnus Persson has been Business Development manager since May 2021, which includes responsibility for identifying building rights as well as executing transactions. Magnus has previously had the same role in BoKlok/Skanska, where he was also a member of BoKlok’s Swedish management team. Magnus Persson has also worked for, among others, Länsförsäkringar fastighetsförmedling, Modulenthus and NCC. For more information, please contact:Jacob Karlsson, CEO, e-mail: jacob.karlsson@k-

BioStock: Elicera Therapeutics enters agreement with BioNTech

Fri, Nov 12, 2021 08:02 CET

Elicera Therapeutics’ push to develop novel immuno-oncology therapies just received a significant boost. The company has entered into a collaboration with the German contract development and manufacturing organisation BioNTech for the development of viral vectors to be used in Elicera’s ELC-401 project. Elicera expects to initiate a phase I/II trial with the CAR T-cell candidate in glioblastoma multiforme patients during the second half of 2023.Read the article at biostock.se: https://www.biostock.se/en/2021/11/elicera-therapeutics-enters-agreement-with-biontech/ This is a press

MPC Container Ships ASA announces date for Q3 and nine-month 2021 results

Oslo, 12 November 2021 - MPC Container Ships ASA (the "Company") will be releasing its third quarter 2021 report prior to market opening on Thursday 18 November 2021. The Company will host a webcast for the presentation of the Q3 2021 results commencing on Thursday 18 November 2021 at 15:00 hours CET / 09:00 hours EDT. The presentation will be made available on the Company’s webpage from 12:00 hours CET / 06:00 hours EDT. There will be a Q&A session after the presentation. The event is being streamed. It is recommended that you

Enfo Group’s interim report Q3 July 1 – September 30, 2021

Enfo Q3/2021: Net sales improvedQ3/2021 · Net sales during July–September were EUR 23.1 (21.4) million · EBITDA was EUR 1.9 (1.3) million · Operating profit (EBIT) was EUR -0.3 (-1.0) million · Profit for the period was EUR -0.7 (-1.1) million · Earnings per share were EUR -1.0 (-1.5) · Operating cash flow was EUR -0.7 (1.0) million Q1-Q3/2021 · Net sales during January–September were EUR 76.4 (74.8) million · EBITDA was EUR 5.2 (5.0) million · Operating profit (EBIT) was EUR -2.3 (-1.8) million · Profit for the period was EUR -3.5 (-2.9) million ·

AZN: Year to date and Q3 2021 results

AstraZeneca PLC 12 November 2021 07:00 GMT Year to date and Q3 2021 results AstraZeneca reinforces its scientific leadership through exceptionalpipeline delivery and the addition of Alexion in the quarter - Total Revenue in the year to date, including Alexion from 21 July 2021, was $25,406m, representing growth of 32% (28% at CER). Total Revenue in the third quarter increased by 50% (48% at CER) to $9,866m - Excluding the pandemic COVID-19 vaccine, Total Revenue increased 21% (17% at CER) in the year to date to $23,187m, and by 34% (32% at CER) in the quarter to $8,

Financial Calendar 2022

Financial Calendar for North Investment Group AB (publ) - ISIN: SE0015938493FINANCIAL YEAR 2022 28.02.2022 - Quarterly Report - Q4 26.04.2022 – Annual Report 12.05.2022 – Quarterly Report – Q1 26.08.2022 – Half-yearly Report – Q2 11.11.2022 – Quarterly Report – Q3

North Investment Group AB - Q3 2021

Q3 2021 Interim financial reportFINANCIAL HIGHLIGHTS · Group revenue of SEK 203.1m (SEK 186.6m). · Gross profit margin 38.6% (38.5%). · EBITDA of SEK 29.8m (SEK 30.2m). · Net operating cash flow SEK 24.7m (SEK 32.5m). · 3PL services in Sweden established with success. · Corporate bond listed on Nasdaq Stockholm 2[nd] November. · Freight prices and raw material prices still on historic high level. · Merge in Sweden finalized 1[st] November. · Order backlog of SEK 138.4m (SEK 85.3m).

Hansa Biopharma Nomination Committee formed

Lund November 12, 2021. Hansa Biopharma today announced that the Nomination Committee has been formed in accordance with the principles adopted by the Annual General Meeting (AGM) on May 12, 2021 and has the following composition: · Natalie Berner representing Redmile Group · Lotta Sjöberg representing Handelsbanken Fonder · Jannis Kitsakis representing AP4 As the conveyer of the Nomination Committee, Ulf Wiinberg, Chairman of the Board of Directors at Hansa Biopharma will be asked to summon the first meeting in the Nomination Committee. The function of the Nomination

Remedy Entertainment Plc: Q3 Business Review: Business progressed as planned, outlook unchanged

Remedy Entertainment Plc | Company announcement 09:00 am (EET) 12 November 2021BUSINESS REVIEW January– September 2021 (unaudited) Business progressed as planned, outlook unchanged Alan Wake Remastered announced and completed for launch HIGHLIGHTS IN JULY–SEPTEMBER 2021 · Revenue was 7 398 (9 914) thousand euros and decreased -25.4 % year-on-year primarily due to a decline in Control royalties and reduced development fees from our Smilegate partnership. · Operating profit (EBIT) was 290 (3 443) thousand euros. The decrease was mainly due to a very strong comparison period

K-Fast Holding AB (publ): Interim report January–September 2021

Financial ratios for the period 1 January–30 September 2021 +----------------+---------+---------+---------+---------+--------+| Financial | 2021 | 2020 | 2021 | 2020 | 2020 ||ratios | Jul–Sep | Jul–Sep | Jan–Sep | Jan–Sep |Jan–Dec |+----------------+---------+---------+---------+---------+--------+| Rental income,| 68.2 | 51.0 | 190.7 | 147.7 | 203.9 ||SEK million | | | | | |+----------------+---------+---------+---------+---------+--------+| Profit from | 29.8 | 21.2 |

Peab builds nursing home in Oslo